International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 507-510 , May 2010

Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics

  • Takashi Niwa

      Affiliations

    • Department of Pharmacy, Gifu University Hospital, Gifu, Japan
    • Center for Nutritional Support & Infection Control, Gifu University Hospital, Gifu, Japan
    • ,
  • Yoshinori Imanishi

      Affiliations

    • Department of Pharmacy, Gifu University Hospital, Gifu, Japan
    • ,
  • Tomofumi Ohmori

      Affiliations

    • Department of Pharmacy, Gifu University Hospital, Gifu, Japan
    • ,
  • Katsuhiko Matsuura

      Affiliations

    • Department of Pharmacy, Gifu University Hospital, Gifu, Japan
    • ,
  • Nobuo Murakami

      Affiliations

    • Center for Nutritional Support & Infection Control, Gifu University Hospital, Gifu, Japan
    • ,
  • Yoshinori Itoh

      Affiliations

    • Department of Pharmacy, Gifu University Hospital, Gifu, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 58 230 7080; fax: +81 58 230 7093.

Received 9 December 2009 ,Accepted 22 December 2009.

References 

  1. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother. 1996;37:209–222
  2. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009;53:4069–4079
  3. Rowland M. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 1990;18:184–209
  4. Wilson APR. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000;39:167–183
  5. Harding I, MacGowan AP, White LO, Darley ESR, Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother. 2000;45:835–841
  6. Sato M, Chida K, Suda T, Muramatsu H, Suzuki Y, Hashimoto H, et al. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. J Infect Chemother. 2006;12:185–189
  7. Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother. 2003;51:971–975
  8. Darley ESR, MacGowan AP. The use and therapeutic drug monitoring of teicoplanin in the UK. Clin Microbiol Infect. 2004;10:62–69
  9. Brink AJ, Richards GA, Cummins RR, Lambson J. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalized patients treated for sepsis. Int J Antimicrob Agents. 2008;32:455–458
  10. Bonati M, Traina GL, Villa G, Salvadeo A, Gentile MG, Fellin G, et al. Teicoplanin pharmacokinetics in patients with chronic renal failure. Clin Pharmacokinet. 1987;12:292–301
  11. Niwa T, Tokuma Y, Ito T, Kimura J, Tabata K, Takagi A. Development of software for data analysis by therapeutic drug monitoring of teicoplanin, a glycopeptide antibiotic. Jpn J Antibiot. 2004;57:413–419
  12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  13. Rybak MJ, Bailey EM, Reddy VN. Clinical evaluation of teicoplanin fluorescence polarization immunoassay. Antimicrob Agents Chemother. 1991;35:1586–1590
  14. de Lalla F, Tramarin A. A risk–benefit assessment of teicoplanin in the treatment of infections. Drug Saf. 1995;13:317–328
  15. Pea F, Viale P, Candoni A, Pavan F, Pagani L, Damiani D, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet. 2004;43:405–415

PII: S0924-8579(10)00020-8

doi: 10.1016/j.ijantimicag.2009.12.018

International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 507-510 , May 2010

Article Tools

* Image Usage & Resolution